Right Science, Right Team, Right Timing
Commercializing a Breakthrough Epilepsy Drug, Aiming for Fast-Track Approval, and New Neurological Treatments
Multi-Pathway Neurotherapeutic for Refractory Epilepsy
Value Inflection Points
- Phase IIb regulatory readiness established
- Animal-to-human translation de-risked
- Brain-penetrant CNS formulation locked
- Biomarkers validated for precision dosing
- AI-enabled translational platform differentiated
Unlocks US$11M
“After examining CanaQuest's portfolio, I recognize the opportunity for CQ-001 to build on the successes of previously approved cannabidiol-based medications. With its combination of active compounds, preliminary data suggests that CQ-001 may offer enhanced benefits by targeting multiple mechanisms of action beyond those of cannabidiol alone.”
Jordyn Stuart, PhD
Former GW Pharma
CNS: central nervous system